Doravirine/lamivudine/tenofovir
Doravirine/lamivudine/tenofovir, a wɔtɔn wɔ Delstrigo din ase no yɛ aduro a wɔde di HIV/AIDS ho dwuma[1]. Ɛwɔ doravirine, lamivudine, ne tenofovir disoproxil[2][3]. Wɔnom[1].
Wɔ United States no, Food and Drug Administration (FDA) penee so sɛ wɔde bɛsa HIV-1 yareɛ wɔ August 2018 mu[4][5][6].
Baabi a menyaa mmoa firiiɛ
[sesa]- ↑ 1.0 1.1 DailyMed - DELSTRIGO- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated, retrieved 2024-09-21
- ↑ "Human medicines European public assessment report (EPAR): Delstrigo, doravirine / lamivudine / tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 1, Status: Authorised", Case Medical Research, 2019-03-14, doi:10.31525/cmr-86415b, ISSN 2643-4652, retrieved 2024-09-21
- ↑ "New product intros (albuvirtide, anakinra (new indication), cemiplimab-rwlc, damoctocog alfa pegol, doravirine, doravirine/lamivudine/tenofovir disoproxil fumarate (new combination), duvelisib, pyrotinib maleate, tafenoquine succinate, testosterone gel (new formulation)", Drugs of Today, vol. 54, no. 10, p. 639, 2018, doi:10.1358/dot.2018.54.10.2903215, ISSN 1699-4019, retrieved 2024-09-21
{{citation}}: line feed character in|title=at position 60 (help) - ↑ "Human medicines European public assessment report (EPAR): Delstrigo, doravirine / lamivudine / tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 1, Status: Authorised", Case Medical Research, 2019-03-14, doi:10.31525/cmr-86415b, ISSN 2643-4652, retrieved 2024-09-21
- ↑ Linda Rhodes (2018-05), "Changing innovation into a registered product: From concept to regulatory approval", Theriogenology, vol. 112, pp. 75–81, doi:10.1016/j.theriogenology.2017.07.001, ISSN 0093-691X, retrieved 2024-09-21
{{citation}}: Check date values in:|date=(help) - ↑ "FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma", Case Medical Research, 2018-11-09, doi:10.31525/fda1-ucm625705.htm, ISSN 2643-4652, retrieved 2024-09-21